Berberine
Isoquinoline alkaloid — AMPK activator with glucose-lowering and lipid-modifying effects
Unregulated by FDA
for efficacy/purity
Version 2025-04 · Last Reviewed April 1, 2025
About this review (v2025-04, last reviewed April 1, 2025): This review was compiled from peer-reviewed clinical trials, independent laboratory analyses, and regulatory filings. Supplement manufacturers had no editorial input. Funding sources for cited studies are disclosed where available. Read our full methodology
This content is for educational purposes only. Supplements are not FDA-approved to treat, cure, or prevent any disease. Discuss supplementation with your healthcare provider before starting, especially if you take medications.
What it is
A yellow isoquinoline alkaloid found in the roots and bark of several plants including Berberis aristata (Indian barberry) and Coptis chinensis (goldthread). Berberine activates AMPK (AMP-activated protein kinase), the same metabolic enzyme targeted by metformin. This activation affects glucose metabolism, insulin sensitivity, lipid synthesis, and gut microbiome composition.
Why form matters
Berberine HCl has poor absolute oral bioavailability (< 5%) due to efflux transporter activity in the gut wall. Despite this, the clinical trials showing significant glucose-lowering effects used standard HCl — suggesting gut-level activity and portal circulation effects are clinically meaningful even at low systemic levels. Enhanced-absorption forms (phytosome, dihydroberberine) exist and show pharmacokinetic advantages, but large clinical endpoint trials still use the HCl form. Sourcing matters as much as form — manufacturing quality from Chinese suppliers varies significantly.
Molecular Forms — What the Research Actually Used
The form in the bottle determines how much actually reaches your bloodstream.
Absorption: Low absolute bioavailability (<5%) but clinically active
The form used in all major glucose and lipid trials. Despite poor systemic absorption, consistent clinical effects suggest gut-level and portal circulation activity. The reference form — use when comparing to research.
Absorption: ~5× higher plasma levels than HCl in some studies
Complexing berberine with phosphatidylcholine improves intestinal absorption. May allow lower doses with equivalent or greater systemic effect. Fewer GI side effects reported. Pharmacokinetic data is preliminary — clinical endpoint trials are still using HCl.
Absorption: ~5× higher than berberine HCl (absorbed and converted to berberine)
A reduced form absorbed more efficiently and converted back to berberine in intestinal cells. GlucoVantage® is a proprietary DHB product with early promising PK data. Not yet validated in large clinical endpoint trials.
Dosing — What the Research Used
Blood glucose / HbA1c reduction (type 2 diabetes adjunct)
Yin et al. 2008 (head-to-head vs metformin); Zhang et al. 2010 meta-analysis
Lipid-lowering (LDL and triglycerides)
Kong et al. 2004; Pirillo & Catapano 2015 review
Berberine phytosome (if using enhanced-absorption form)
Follow product-specific pharmacokinetic data
Note: Berberine should be taken with or immediately before meals — this improves absorption and reduces GI side effects (nausea, constipation, diarrhea), which occur in a meaningful proportion of users. Because berberine lowers blood glucose, anyone on diabetes medication must monitor blood sugar closely when starting, stopping, or adjusting doses.
Frequently Asked Questions About Berberine
- What is Berberine?
- A yellow isoquinoline alkaloid found in the roots and bark of several plants including Berberis aristata (Indian barberry) and Coptis chinensis (goldthread). Berberine activates AMPK (AMP-activated protein kinase), the same metabolic enzyme targeted by metformin. This activation affects glucose metabolism, insulin sensitivity, lipid synthesis, and gut microbiome composition.
- What does Berberine do?
- Berberine has demonstrated glucose-lowering effects comparable to metformin in several Chinese RCTs. However, these trials were conducted in Chinese populations with different dietary contexts, and large independent Western replication is still limited. The drug interaction profile — particularly CYP2C9 inhibition (warfarin), broad CYP3A4 inhibition, and AMPK overlap with metformin — makes berberine one of the highest-interaction supplements in common use. The 'nature's metformin' narrative dramatically understates this risk.
- What is the typical dose of Berberine?
- Berberine should be taken with or immediately before meals — this improves absorption and reduces GI side effects (nausea, constipation, diarrhea), which occur in a meaningful proportion of users. Because berberine lowers blood glucose, anyone on diabetes medication must monitor blood sugar closely when starting, stopping, or adjusting doses.
- Does Berberine interact with any medications?
- Berberine has known interactions with: Metformin — Berberine and metformin activate AMPK through overlapping pathways. Combining may cause additive or synergistic blood glucose lowering with increased hypoglycemia risk. This combination requires blood glucose monitoring and physician coordination.; Sulfonylureas (glipizide, glibenclamide) — Sulfonylureas lower blood glucose through insulin release. Adding berberine's glucose-lowering effects substantially increases hypoglycemia risk. Do not combine without medical supervision.; Warfarin (Coumadin) — Berberine inhibits CYP2C9, the enzyme primarily responsible for warfarin metabolism. This may substantially increase warfarin plasma levels and bleeding risk. INR must be closely monitored if berberine is initiated or stopped in someone on warfarin.; CYP3A4 substrates (many medications) — Berberine inhibits CYP3A4, which metabolizes approximately 50% of all drugs — including many statins, immunosuppressants, antifungals, and cardiovascular medications. Potential for drug level elevation when combined with these medications..
- Who should be cautious about taking Berberine?
- Exercise caution or consult a healthcare provider if you are: Pregnancy — berberine crosses the placenta and has uterotonic activity in animal studies. Contraindicated in pregnancy.; Neonates and nursing infants — berberine can displace bilirubin from albumin, potentially causing jaundice. Not for nursing mothers.; Anyone on multiple medications — the CYP3A4 and CYP2C9 inhibition profile creates broad drug interaction risk. Pharmacist or physician review required before starting.; People already on glucose-lowering medications — combination requires active blood glucose monitoring to avoid hypoglycemia..
Get notified when we update Berberine
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.